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Summary
Over the past decade, use of autologous bone marrow-de-
rived mononuclear cells (BMCs) has proven to be safe
in phase-I/II studies in patients with myocardial infarction
(MI). Taken as a whole, results support a modest yet sig-
nificant improvement in cardiac function in cell-treated
patients. Skeletal myoblasts, adipose-derived stem cells,
and bone marrow-derived mesenchymal stem cells (MSCs)
have also been tested in clinical studies. MSCs expand rap-
idly in vitro and have a potential for multilineage differenti-
ation. However, their regenerative capacity decreases with
aging, limiting efficacy in old patients. Allogeneic MSCs
offer several advantages over autologous BMCs; however,
immune rejection of allogeneic cells remains a key issue.
As human MSCs do not express the human leukocyte an-
tigen (HLA) class II under normal conditions, and because
they modulate T-cell-mediated responses, it has been pro-
posed that allogeneic MSCs may escape immunosurveil-
lance. However, recent data suggest that allogeneic MSCs
may switch immune states in vivo to express HLA class II,
present alloantigen and induce immune rejection. Allogen-
eic MSCs, unlike syngeneic ones, were eliminated from rat
hearts by 5 weeks, with a loss of functional benefit. Allo-
geneic MSCs have also been tested in initial clinical stud-
ies in cardiology patients. Intravenous allogeneic MSC in-
fusion has proven to be safe in a phase-I trial in patients
with acute MI. Endoventricular allogeneic MSC injection
has been associated with reduced adverse cardiac events in
a phase-II trial in patients with chronic heart failure. The
long-term safety and efficacy of allogeneic MSCs for car-
diac repair remain to be established. Ongoing phase-II tri-
als are addressing these issues.
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Introduction
Growing evidence suggests that the adult mammalian heart
harbours stem and progenitor cells that possess a regener-
ative capacity [1]. Moreover, circulating bone marrow-de-
rived progenitor cells can home to injured myocardium to
participate in cardiac repair [2]. Nevertheless, myocardial
infarction (MI) results in a massive loss of cardiomyocytes
and scar formation. Hence, endogenous regenerative mech-
anisms appear to be insufficient to replace the huge num-
ber of cardiomyocytes that are lost after MI. Chronic heart
failure (CHF) eventually ensues in many patients. Recent
advances in pharmacological agents, coronary revascular-
isation and implantable devices have succeeded in allevi-
ating clinical symptoms, prolonging survival and slowing
down the progression of CHF; however, they have failed to
fully prevent CHF. As a loss of cardiomyocytes is primarily
responsible for the development of CHF, the generation of
new functional cardiomyocytes remains the ultimate goal
for preserving cardiac function.
Ten years ago, a seminal report claimed that adult mouse
bone marrow-derived stem cells trans-differentiated into
cardiomyocytes to regenerate infarcted myocardium in vivo
[3]. This report sparked overwhelming enthusiasm in the
scientific community, leading to the extremely rapid ini-
tiation of clinical studies of bone marrow cell (BMC)-
based therapies for cardiac repair [4, 5]. Meanwhile, car-
diomyogenic trans-differentiation of mouse BMCs was not
confirmed by subsequent studies from other laboratories
[6, 7], questioning the very rationale for the initiation of
these clinical studies. The first phase-I study of BMC-
based therapy for ischemic heart disease [5] was published
only 2 years after the initial experimental report on cardi-
omyogenic trans-differentiation of BMCs [3]. Several oth-
er phase-I/II clinical studies were published in the next few
years. Most of these studies adopted a “blanket” strategy
using autologous unfractionated mononuclear BMCs,
rather than selected cell components within the heterogen-
eous BMC population. A few days after acute MI and
percutaneous recanalisation of the infarct-related coronary
artery, bone marrow was taken from the patient, and mono-
nuclear BMCs were prepared in the laboratory and imme-
diately infused into the infarct-related vessel using a percu-
taneous over-the-wire delivery-catheter. Autologous BMC-
based cell therapies for cardiac repair have proven to be
safe in randomised controlled trials [8–12]. In agreement
with these studies, our own data from the phase-I Stem cell
Transplantation in Ischemic Myocardium (STIM) trial (n
= 23 patients) and preliminary data from the subsequent
phase-II SWiss multicentre Intracoronary Stem cells Study
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 1 of 6
in Acute Myocardial Infarction (SWISS-AMI) trial [13] (n
= 166 patients enrolled as of March 31, 2011) indicate that
intracoronary autologous BMC infusion in patients with
acute MI is safe (Corti R, Sürder D, Moccetti T et al.; un-
published data). Efficacy data from randomised controlled
trials have been mixed [8–12]. Taken as a whole, these data
support a small yet significant increase in left ventricular
ejection fraction (EF) in cell-treated patients [14]. Func-
tional improvement seemed to be higher in patients with
moderate-severe ventricular dysfunction than in those with
mild dysfunction [10, 12]. However, in many instances,
functional improvement was transient [15].
Autologous mononuclear BMC-based therapies have sev-
eral limitations. The cell component within the heterogen-
eous BMC population that accounts for functional benefit
has not been precisely defined. Bone marrow stem cells
represent only 1 in 10,000 BMCs [16], and therefore can
hardly explain the beneficial effect of BMC transplanta-
tion. Also, the proliferative and regenerative capacity of
progenitor cells decreases with aging [17, 18], consistent
with a reduced efficacy of progenitor cells from old pa-
tients. Another practical limitation is that the collection of
bone marrow from the patient requires an invasive proced-
ure.
Skeletal myoblasts, adipose-derived stem cells and mesen-
chymal stem cells (MSCs) have also been tested in a lim-
ited number of clinical studies in patients with MI. Ske-
letal myoblasts form contractile striated myocytes that do
not couple electromechanically with cardiomyocytes. Per-
cutaneous intramyocardial injection of autologous skeletal
myoblasts using a cell delivery-catheter has proven safe
but ineffective in the recent SEISMIC trial in patients with
CHF [19]. Intracoronary infusion of autologous adipose-
derived stem cells was proven to be safe in the recent
double-blind, placebo-controlled APOLLO trial in patients
with acute MI [20]. The cell-treated group showed a 5.7%
increase in ejection fraction (EF) and improved myocardial
perfusion, although these effects did not reach statistical
significance in this early trial. The efficacy of adipose-
derived stem cells will be evaluated in the phase-II/III
ADVANCE trial.
The present short review aims to discuss MSC-based ther-
apies after MI, with a focus on allogeneic MSC products.
Experimental studies of autologous
MSCs for cardiac repair
Bone marrow MSCs are multipotent stromal (non haema-
topoietic) cells capable of differentiating into multiple lin-
eages of the mesenchyme to become fat, bone, tendon and
muscle. Cultured MSCs grow rapidly in vitro. Systemic-
ally delivered MSCs can home to sites of ischemia and tis-
sue injury, including the ischemic heart. This remarkable
property allows the non-invasive administration of MSCs
intravenously, thus avoiding the need for intracoronary or
intramyocardial cell delivery. MSCs treated with the de-
methylating agent 5-azacytidine or cardiomyogenic growth
factors can adopt cardiac phenotypes in vitro [21–25]. In
many instances, however, cardiac differentiation has been
limited to the expression of cardiac-specific genes, without
generation of functional cardiomyocytes [26]. Immunohis-
tochemical evidence of cardiomyogenic differentiation of
human MSCs implanted into infarcted mouse hearts has
been reported [27]. Several experimental studies have
shown improvements in cardiac function after MI in an-
imals receiving MSCs [28–33] despite infrequent differ-
entiation [29, 30]. In contrast, no functional benefit was
observed in a minority of studies [34]. Over-expression
of pro-survival molecules (e.g. Akt) by autologous MSCs
significantly enhanced functional recovery after MI [30,
35]. These observations support central roles of paracrine
mechanisms that stimulate angiogenesis and endogenous
cardiac stem cells [36], rather than cell differentiation, in
the therapeutic effects of MSCs.
Clinical studies of autologous MSCs for
cardiac repair
Intracoronary infusion of autologous bone marrow-derived
MSCs significantly increased EF at 3 months in a random-
ised study in patients with acute MI [37]. In addition, auto-
logous MSC transplantation has proven safe in several non-
randomised studies in patients with acute MI or CHF [38,
39]. Newly initiated phase-I/II studies include the Transen-
docardial Autologous Cells (hMSC or hBMC) in Ischemic
Heart Failure Trial (TAC-HFT; www.clinicaltrials.org/
NCT00768066), the Prospective Randomised study Of
MSC THErapy in patients Undergoing cardiac Surgery
(PROMETHEUS) trial (www.clinicaltrials.org/
NCT00587990) which is expected to be completed in
mid-2011, and the Percutaneous Stem Cell Injection De-
livery Effects on Neomyogenesis (POSEIDON) pilot study
(www.clinicaltrials.org/NCT01087996) [40], among oth-
ers.
As MSCs are rare among BMCs, they need to be expanded
ex vivo for autologous applications. This procedure may
take between 10 days [37] to 4-5 weeks [40] or longer de-
pending on the cell number needed, and the age and co-
morbidities of the donor, as progenitor cells from old pa-
tients have reduced proliferation potential [17, 18, 41]. Cell
expansion requires a Good Manufacturing Practice (GMP)
cell therapy unit (Figure 1). Allogeneic MSCs from young
donors have several advantages over autologous MSCs, in-
Figure 1
Good Manufacturing Practice (GMP) cell therapy unit at the
Cardiocentro Ticino, Lugano. GMP facilities are required for ex vivo
expansion of cells used in clinical studies.
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cluding a high regenerative potential and availability for
clinical use at any time point. In addition, no bone marrow
collection from the patient is required. Moreover, MSCs
from a single donor can be used for many patients, thus
tremendously reducing the manufacturing costs of the cell
product. On the other hand, the potential immunogenicity
of allogeneic MSCs remains an unresolved issue that may
affect clinical efficacy.
MSCs can switch immune states
Bone marrow-derived MSCs secrete immunoregulatory cy-
tokines (e.g., IL10) and inhibit lymphocyte proliferation,
dendritic cell maturation and alloimmune rejection
[42–48]. Due to their immunomodulatory properties,
MSCs have been tested in initial clinical studies of graft-
versus-host diseases [49], osteogenesis imperfecta [50],
glycogen storage diseases [51], Crohn's disease [52] and
organ transplantation [53].
MSCs have been shown to express major histocompatib-
ility complex (MHC) molecules, including MHC class II
(MHC-II). Expression of MHC molecules is regulated by
pro-inflammatory cytokines. Adult human MSCs express
intermediate levels of MHC-I but do not express human
leukocyte antigen (HLA) class II or co-stimulatory molec-
ules on the cell surface under normal in vitro conditions.
However, HLA-II has been detected in lysates of unstim-
ulated MSCs, presumably reflecting intracellular depos-
its of the antigen. Treatment with interferon-γ was found
to induce expression of HLA class II on the cell surface
[43]. Another study showed that MSCs express MHC-II as
antigen presenting cells in the presence of low levels of
interferon-γ, whereas MHC-II expression was decreased by
high levels of interferon-γ [54]. Inducing MSCs to acquire
cardiac phenotypes by 5-azacytidine or cytokine treatment
increased expression of immunostimulatory MHC-Ia and
MHC-II, while decreasing that of immunomodulatory
MHC-IIb, resulting in enhanced cytotoxicity of MSCs in
co-culture with allogeneic leukocytes [55]. These observa-
tions suggest that MSCs can switch immune states from
immunomodulatory to immunostimulatory (figure 2).
Several studies have shown delayed host responses to al-
Figure 2
Cartoon depicting MSC immune switch. Under normal in vitro
conditions (left), human MSCs express low MHC-I and no HLA
class II, while secreting IL10. They mediate immunomodulatory
effects on T cells. In the presence of pro-inflammatory cytokines
(right), HLA class II is expressed on cell surfaces. MSCs acquire
antigen presenting cell properties and stimulate T cells.
logeneic MSCs in vivo around 2 weeks after transplanta-
tion, suggesting that tolerance of MSCs across the allogen-
eic barrier may not be absolute [55–58].
Experimental studies of allogeneic
MSCs for cardiac repair
Intravenous [59] or intracoronary infusion, as well as
transendocardial [60] or intramyocardial injection [28, 61,
62] of allogeneic MSCs has resulted in cell engraftment,
reduced scar formation and improved cardiac function in
various animal models of MI. Male MSCs injected into in-
farct scars and border zones in female allogeneic recipients
differentiated towards multiple cell types including car-
diomyocytes, vascular muscle cells and endothelial cells,
as evidenced by co-localisation of Y-chromosome-positive
cells and tissue-specific markers [62]. MSC-derived cardi-
omyocytes integrated into host myocardium, forming gap
junctions. In sheep, intracoronary infusion of allogeneic
mesenchymal progenitor cells (MPCs) improved EF and
blood vessel formation 2 months after MI (Henry T et
al.; www.mesoblast.com). In a rat model, both allogeneic
and syngeneic MSCs improved EF 3 months after MI;
however, allogeneic cells were eliminated from the heart
by 5 weeks and functional benefit was lost within 5 months
[55]. Circulating antibodies against differentiated allogen-
eic MSCs, but not against undifferentiated MSCs, were de-
tected in the recipient by 5 weeks. In contrast, syngeneic
MSCs were not eliminated and functional benefit lasted for
more than 5 months. In a pig model, allogeneic MSCs were
not immunogenic in vitro but elicited immune responses
after intracardiac injection in vivo [58]. These experimental
findings indicate that bone marrow-derived MSCs can in-
duce immune responses in allogeneic hosts.
Clinical studies of allogeneic MSCs for
cardiac repair
The results of the first phase-I, randomised, double-blind,
placebo-controlled, dose-escalation study of intravenous
allogeneic adult MSCs in patients with acute MI were pub-
lished in December 2009 [63]. This study tested an “off-
the-shelf” cell product (ProchymalTM, Osiris Tx.) made
from MSCs of a single healthy donor. A total of 53 patients
who had suffered a first MI in the previous 10 days were
randomised to receive one of three intravenous doses of
ProchymalTM or placebo, without immunosuppression. The
study’s primary end point, adverse event rates at 6 months,
was similar in the cell-treated group and the placebo group,
indicating that the procedure was safe. No procedure-re-
lated complications were observed. Renal, hepatic and
hematologic laboratory indexes were similar in the two
groups. No patient developed tumours. Cell-treated pa-
tients had less episodes of ventricular tachycardia and a
better lung function compared with controls. Although the
study did not primarily aim to assess clinical efficacy, there
was a trend towards improved clinical symptoms and in-
creased EF at 3 months, but not at 6 months, in the cell-
treated group. A phase-II multicentre trial of ProchymalTM
has been started.
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Endoventricular injection of an allogeneic MPC product
(RevascorTM, Mesoblast Ltd.) along the infarct border zone
in patients with moderate-severe CHF has been evaluated
in a phase-II, randomised, single-blind, placebo-controlled,
dose-escalation, multicentre study. There were no
procedure-related complications. The first cohort in the
study (n=20 patients), receiving the low dose of
RevascorTM in the trial, showed a 33% increase in EF at 6
months (p=0.029), whereas EF decreased 6% in the con-
trol group [64]. Interim data analysis after all patients had
reached 6 months follow-up (www.mesoblast.com/news-
room/asx-announcements/archives) showed that the num-
ber of patients who developed any severe adverse cardiac
events over the follow-up period was 44.4% in the cell-
treated group (n=45) versus 93.3% in the control group (n
= 15; p = 0.001). The number of patients who developed
any major adverse cardiac events, defined as the composite
of cardiac death, heart attack or coronary revascularisation
procedures, was 6.7% in the cell-treated group versus 40%
in the control group (p = 0.005).
Conclusions
“Off-the-shelf” allogeneic MSC products have proven safe
in phase-I/II trials in patients with acute MI or CHF [63,
64]. Preliminary efficacy data are encouraging. Several is-
sues remain unresolved, however. Little is known regard-
ing the in vivo survival of allogeneic MSCs. Experimental
evidence suggests allogeneic MSCs may switch immune
states in vivo, inducing alloimmune rejection [55]. The
long-term safety and efficacy of allogeneic MSC-based
therapies for cardiac repair are currently being tested in
phase-II clinical trials. If immunogenicity of human al-
logeneic MSCs turned out to limit the clinical efficacy,
pharmacological immunosuppression for limited periods of
time after cell transplantation might be worth considering
as a possible option, although the effectiveness of this ap-
proach remains to be demonstrated. Moreover, minimizing
donor-recipient HLA-II mismatch might attenuate alloim-
mune rejection of transplanted MSCs. On the other hand,
paracrine mechanisms of action [35] suggest that long-term
survival of transplanted MSCs might not even be required
to achieve sustained clinical effects.
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